2Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part Ⅰ : natural history, pathogenesis, diagnosis, and prognosis[J]. Lancet Neurol, 2005,4(5) :281 -288.
3Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelination event[J]. N Engl J Med,2003, 349(2) :139 - 145.
6Wingerchuk DM, Hongacamp WF, O'Brien PC, et al. The clinical course of nemomyelitis optica ( Devic's syndrome) [ J ]. Neurology, 1999,53(5) :1107 -1114.
7Lucchinetti CF, Mandler RN, McGavem D, et al. A role for humoral mechanisms in the pathogenesis of Devic ' s neuromyelitis optica [ J ]. Brain ,2002,125( Pt7 ) : 1450 - 1461.
8Rocca MA, Agosta F, Mezzapesa DM, et al. Magnetization transfer and diffusiontensor MRI show gray matter damage in neuromyelitis optica [J]. Neurology,2004,62(3) : 476 -478.
8Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain, 1997, 120 ( Pt 11 ) : 2059- 2069.
9Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol, 2006, 27: 455- 461.
10Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist, 2007, 13 : 2-11.
